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Abstract
Background: Accurate reporting on sex and gender in health research is integral to ensuring that health
interventions are safe and effective. In Canada and internationally, governments, research organizations, journal
editors, and health agencies have called for more inclusive research, provision of sex-disaggregated data, and the
integration of sex and gender analysis throughout the research process. Sex and gender analysis is generally
defined as an approach for considering how and why different subpopulations (e.g., of diverse genders, ages, and
social locations) may experience health conditions and interventions in different or similar ways.
The objective of this study was to assess the extent and nature of reporting about sex and/or gender, including
whether sex and gender analysis (SGA) was carried out in a sample of Canadian randomized controlled trials (RCTs)
with human participants.
Methods: We searched MEDLINE from 01 January 2013 to 23 July 2014 using a validated filter for identification of
RCTs, combined with terms related to Canada. Two reviewers screened the search results to identify the first 100
RCTs that were either identified in the trial publication as funded by a Canadian organization or which had a first or
last author based in Canada. Data were independently extracted by two people from 10% of the RCTs during an
initial training period; once agreement was reached on this sample, the remainder of the data extraction was
completed by one person and verified by a second.
Results: The search yielded 1433 records. We screened 256 records to identify 100 RCTs which met our eligibility
criteria. The median sample size of the RCTs was 107 participants (range 12–6085). While 98% of studies described
the demographic composition of their participants by sex, only 6% conducted a subgroup analysis across sex and
4% reported sex-disaggregated data. No article defined “sex” and/or “gender.” No publication carried out a
comprehensive sex and gender analysis.
Conclusions: Findings highlight poor uptake of sex and gender considerations in the Canadian RCT context and
underscore the need for better articulated guidance on sex and gender analysis to improve reporting of evidence,
inform policy development, and guide future research.
Keywords: Sex/gender analysis, Gender, Randomized controlled trials as a topic, Canada, Quality
* Correspondence: Vivian.Welch@uottawa.ca
1Bruyère Research Institute, Bruyère Continuing Care, 304b-85 Primrose
Avenue, Ottawa, Ontario K1R 6 M1, Canada
2University of Ottawa, Ontario, Canada
Full list of author information is available at the end of the article
Research Integrity and
           Peer Review
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Welch et al. Research Integrity and Peer Review  (2017) 2:15 
DOI 10.1186/s41073-017-0039-6
Background
Over the past several decades, there has been increasing
awareness within the community of health researchers, fun-
ders, and knowledge users (e.g., policy-makers, practi-
tioners, and patients) of the need to understand how sex
and gender influence health outcomes [1, 2]. “Sex” is com-
monly used to refer to genetic, biological, and physiological
processes; whereas “gender” is commonly used to refer to
the roles, relationships, behaviors, relative power, and other
traits that societies ascribe to women, men, and people of
diverse gender identities [3]. Sex and gender interact with
each other and other characteristics to influence health out-
comes [4–9]. For example, research indicates there are sig-
nificant physiological differences in cardiac function
between males and females such as susceptibility to QT
interval prolongation and serious heart arrhythmias as well
as gender differences in how men and women who have
heart disease are diagnosed and treated [10–12]. Failure to
take these differences into account, not just between men
and women, but also across other characteristics such as
age and socioeconomic status, can have serious, even life-
threatening, consequences for individual patients.
As used in this paper, sex and gender analysis is an ap-
proach and framework for considering fundamental
questions about how and why different subpopulations
(e.g., of diverse genders, ages, and social locations) may
experience health conditions and interventions in differ-
ent or similar ways. These fundamental questions are
systematically applied to all stages of the research
process, starting with the formulation of the initial re-
search question, followed by the development of meth-
odology, conduct of the analysis, and interpretation of
results and reflecting on their implications [13–16].
Policies and guidance increasingly mandate or recom-
mend routine collection, reporting and analysis of the influ-
ence of sex and gender in scientific research. However,
uptake of sex and gender analysis, and its impacts on
reporting and on health outcomes remain unclear [2, 17,
18]. For example, funding policies of the U.S. National In-
stitutes of Health (Revitalization Act 1993) [19], mandating
the appropriate inclusion of women and minorities in clin-
ical trials have resulted in increased inclusion of diverse
populations in some areas of health research [20, 21] but
not all [22]. Furthermore, sex and gender analysis to assess
similarities or differences in health outcomes remains lim-
ited [23]. In the Canadian federal context, neither Health
Canada’s 1997 Guidance Document on Inclusion of
Women in Clinical Trials nor the more detailed May 2013
document that replaced it, “Considerations for Inclusion of
Women in Clinical Trials and Analysis of Sex Differences”
[24], provide mechanisms to track implementation of this
guidance by researchers and sponsors of clinical trials in
Canada to identify outcomes in relation to sex and gender
considerations. In 2011, the Canadian Institutes of Health
Research (CIHR) implemented a requirement that all re-
search grant applicants indicate whether their research
proposal addresses sex and gender and to provide justifi-
cation for their response [25, 26]. The preliminary results
assessing the implementation of this policy indicate in-
creased consideration of sex and gender in most categor-
ies of research proposals [26], but the impact of the policy
on the conduct and reporting of research, including ran-
domized controlled trials (RCTs), has yet to be examined.
The objective of this study was to provide a prelimin-
ary assessment of the extent and nature of reporting
about sex and/or gender, including whether sex and gen-
der analysis was carried out, in a sample of recently pub-
lished Canadian RCTs with human participants.
Methods
A collaborative research team (all authors on this paper)
engaged in a deliberative, consensus building process
and team meetings conducted to plan, develop, and con-
duct a cross-sectional study to meet our objective.
Consensus was reached on a data extraction form and
methods for the study. Our working definitions of sex and
gender were adapted from the Canadian Institutes of
Health Research, Canada’s health research funding agency,
which recognizes sex and gender as analytically distinct
but interdependent concepts and which also acknowledges
the nuances of sex and gender beyond the binary [27].
For the purposes of our search, Canadian trials were de-
fined as those that were either identified in the publication
as funded by a Canada-based funder and/or had a first or
last author with affiliation based in Canada. To account
for the diverse nature of Canadian trials, which can in-
volve cross-border and inter-sectoral collaborations, we
included multi-centre trials, as well as trials funded jointly
by Canadian and international sources. We did not restrict
inclusion on the basis of age (e.g., children, adolescents)
or whether the trial focused on specific populations (in-
cluding across sex and/or gender). We chose a sample size
of 100 RCTs based on the sample size of other similar
methodological studies [23, 28, 29]. This sample size of
100 trials will detect a proportion of 25% with a 95% con-
fidence interval of ±8.5%.
A search strategy was developed in consultation with a
librarian scientist (TR) to identify Canadian RCTs con-
ducted with human participants. This strategy comprised
a MEDLINE search using the OVID interface with the
specific filter (randomized controlled trial.pt OR random-
ized controlled trial.mp) combined with Canadian prov-
inces/territories (Quebec or Ontario or “Prince Edward
Island” or New Brunswick or Nunavut or “Northwest
Territories” or Nova Scotia or Newfoundland or Labrador
or Yukon or British Columbia or Manitoba or Alberta or
Saskatchewan).in OR (Canadian or Canada).in) from 01
January 2013 to 23 July 2014. We chose to search
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MEDLINE up to 1 year prior to data collection because
most articles would be indexed according to Medical Sub-
ject Headings by this time, allowing the use of the specific
filter for randomized trials.
Two authors screened records independently (duplicate
screening) in order of date of publication, starting with the
most recent, to identify those RCTs meeting eligibility
criteria.
A data extraction form was developed and pre-tested to
capture data on the type of intervention, study design
(cluster or individually randomized trial), sample size, and
funding sources. We assessed whether sex and gender
analysis was conducted, what was done and how this was
reported, drawing from items in the PRISMA-Equity ex-
tension [30] and the European Association of Science
Editors (EASE) guidance [31]. Details on whether sex or
gender were mentioned and in what context were col-
lected from the title/abstract, introduction, methods, eligi-
bility criteria, population characteristics, results, subgroup
analysis, interpretation of applicability, and discussion. We
also collected data on reporting of social determinants of
health (e.g., socioeconomic status, occupation, place of
residence) which will be reported in a separate paper
(contact first author for details) (see Additional file 1:
Appendix 1 for complete list of data extraction items).
Data were independently extracted by two people from
10% of the RCTs as a training exercise: once agreement
was reached on this sample [32] the remainder of the data
extraction was completed by one person (one of TB, LQ,
and MY) and was verified by a second (one of JJ, VW).
We included both primary publications of RCTs as well
as secondary publications (i.e., secondary analyses on RCTs
that had already been published). For 13 secondary publica-
tions, we identified the primary RCT publication and used
that as the basis for the data extraction, and supplemented
with information from the secondary publication. Second-
ary publications were included because subgroup analyses
are sometimes reported in secondary, follow-up publica-
tions rather than in the primary trial report.
Results
Search results
The search identified 1433 records. We screened 256 re-
cords from the most recent to the oldest to identify the
first 100 eligible RCTs. Of the ineligible records, 120
were excluded because they were not RCTs or involved
non-human subjects. We also excluded 36 RCTs that
did not have a Canadian funder or a first or last author
based in Canada (Fig. 1).
Description of the sample
Inclusion criteria
Canadian funding was reported in 68/100 of the RCTs
(68%), while the remaining 32 trials were eligible for
inclusion in the sample on the basis of having a first or last
author based in Canada. Of these 32 trials, 13 were funded
by non-Canadian sources and 19 did not report on any
sources of funding. Of the 81 RCTs that did report on fund-
ing sources, 37 identified non-profit sources of funding; 22
identified government sources (e.g., Canadian Institutes of
Health Research, Health Canada); 10 indicated they were
solely funded by industry; while 8 RCTs identified a com-
bination of non-profit and government sources; 2 identified
non-profit and industry funding and 2 identified govern-
ment and industry sources of funding (Additional file 2:
Appendix 2).
Population
We classified trials as “single-sex” and “mixed-sex”, based
on the terminology used by Gendered Innovations [33].
Twelve RCTs were classified as single-sex studies because
they had eligibility criteria that restricted participation to
women, one RCT enrolled girls and one RCT enrolled
boys. The remainder of RCTs were classified as mixed-sex
because they enrolled male and female participants.
Eighty-five out of 88 mixed-sex RCTs reported the num-
ber of enrolled male and female participants. For these,
the median number of male participants was 45 (range 3–
3843) and the median number of female participants was
53 (range 1–1712). As shown in Table 1, the median sam-
ple size of the 100 RCTs was 103 (range 20–1466) for sin-
gle sex studies and 107 participants (range 12–6085) for
Fig. 1 Study flow chart
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mixed-sex studies. As noted, we did not restrict inclusion
on the basis of age or focus on specific populations. Two
trials did not provide any information about the sex of the
population, referring to the population as patients or
nurses/care aides.
Multi- and single site
Of the 100 RCTs, 42 were reported as multi-site and 58
were single-site RCTs. Not all trials provided informa-
tion on the study site(s) (Table 1). In the subset of
multi-site trials that did report information on site loca-
tion, 27/42 (64%) were conducted entirely within Canada
and only one out of the remaining 15 included no sites
within Canada. In single-site RCTs reporting location,
the majority (55/58 or 95%) were conducted in Canada,
2 RCTs were conducted in other countries but had
Canadian first or last authors and one RCT did not de-
scribe site location.
Types of interventions
The interventions included in the sample of 100
RCTs were highly diverse. These included 52 non-
pharmacological interventions, such as rehabilitation
techniques, food supplements (e.g., canola oil and
ginseng), and cognitive behavior interventions; 37
pharmacological interventions, (e.g., the use of simva-
statin in hypertension); 6 surgical interventions, (e.g.,
coronary artery bypass grafting); and 5 organizational
interventions (e.g., simulation-based training for lap-
aroscopic inguinal repair) (see complete list of in-
cluded studies in Additional file 3: Appendix 3).
Reporting of sex/gender in RCTs
Sex and gender terminology in RCTs
The terminology used by authors to describe the partici-
pant demographic composition by “sex or gender” var-
ied. For example, some trials used the term gender and
some used sex. No RCT provided or referenced a defin-
ition of sex or gender or of sex and gender analysis. No
studies reported on inclusion of gender diverse partici-
pants (e.g., transgender, gender non-binary, or other
gender identities). Similarly, no studies used the term
cisgender or transgender to describe the populations.
For this reason, reference to males and females in this
review and in the source references is assumed to refer
to cisgender females and males according to Schilt and
Westbrook’s (2009) definition of cisgender referring to
“individuals who have a match between the gender they
were assigned at birth, their bodies, and their personal
identity” (p. 461) [34]. Because the RCTs varied in the
use of terms related to sex and gender, we use the ex-
pression sex or gender to report the results.
Reporting of sex or gender in the sample of RCTs
None of the RCT authors stated that they intended to
conduct sex and gender analysis, nor did any do so.
The extent to which sex or gender was reported across
various sections of RCT publications varied consider-
ably, as shown in Fig. 2. We provide examples of report-
ing to illustrate each section.
Title/abstract of RCTs
In the title or abstract, 19 (19%) RCTs reported on some
aspect of sex or gender.
Fig. 2 Reporting of sex and/or gender in RCTs
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Single-sex studies In the title or abstract, 11 out of 12
(92%) single-sex RCTs reported some aspect of sex or gen-
der. For four of these, the population was defined in the
title. For example, “Effect of a Novel Movement Strategy
in Decreasing ACL Risk Factors in Female Adolescent
Soccer Players: A Randomized Controlled Trial” [35].
Mixed-sex studies Eight out of 88 (9%) RCTs reported
on some aspect of sex or gender, and this was men-
tioned only in the abstract.
Background/rationale of RCTs
In the rationale or background section, sex or gender
was only mentioned in 11 (11%) of the RCTs. Single-sex
studies: 5 out of 12 single-sex RCTs (42%) reported on
sex or gender in the background section. Three of the
RCTs reported information on prevalence or importance
of a condition in subpopulations. Two of these studies
reported a rationale related to sex or gender.
Mixed-sex studies Six out of 88 mixed-sex RCTs (7%)
reported sex or gender information in the background
section. One RCT reported information on prevalence
across sex or gender. For example, one RCT stated that
“…symptomatic knee OA (ed: osteoarthritis) occurs in
10% of men and 13% of women ages 59 years
(pg.1837)” [36]. Five RCTs reported a rationale related to
why the intervention might work differently across sex
or gender or provided background evidence about differ-
ential effects. For example, one study of compression
technologies for leg ulcer care stated in the background
that, “women did more poorly according to one study,
but two other studies found no significant effect of gen-
der (pg. 1834)” [37]. Of these six studies, none report
analyzing the effect of sex or gender but three RCTs dis-
cuss applicability of results with regards to sex or
gender.
Eligibility criteria of RCTs
Single-sex studies All 12 single-sex RCTS described an
exclusion based on sex or gender. Two of these 12 RCTs
(1 with pharmacological intervention and 1 with non-
pharmacological intervention) excluded pregnant/breast-
feeding women.
Mixed-sex studies Twenty-one of the 88 mixed-sex RCTs
(24%) described exclusion criteria based on sex or gender.
Twelve RCTs excluded pregnant/breastfeeding women, 1
excluded women of child-bearing age, and 4 RCTs excluded
both pregnant women and women of childbearing age.
Thirteen of these 17 RCTs evaluated pharmacological inter-
ventions. For example, one pharmacological intervention
using “low (50 mg/day) or high (200 mg/day) dose of
Losartan” excluded “pregnant and lactating women”(pg.
590) [38] and another using a “supplement with a high-
dose micronutrient, mineral and antioxidant preparation
(K-PAX UltraH) or an identically appearing 100% RDA
preparation of multivitamins and minerals” had exclusion
criteria that included “HIV-2 infection alone, pregnancy or
not willing to practice barrier method of birth control” (pg.
3) [39]. Of the remaining four RCTs that excluded preg-
nant/breastfeeding women or women of child-bearing age,
two RCTs were non-pharmacological interventions, one
surgical, and one organizational intervention. No studies
discuss the rationale or risk considerations for excluding on
the basis of pregnancy.
Intervention description in RCTs
Only one mixed-sex RCT took sex or gender into ac-
count when describing the characteristics of how an
intervention was implemented. In that study, authors re-
ported using a “male and female team” to present educa-
tional sessions on managing side effects of androgen
deprivation therapy (ADT) and the impact on couples
[40]. The rationale provided was: “so that attendees
would understand that the program was meant to serve
equally the concerns of the male patient and the female
partner (in heterosexual couples) (pg. 228)” [40].
Description of participants in RCTs
Almost all RCTs (98%) reported demographic character-
istics by sex or gender by identifying number of male/fe-
male participants in text or as part of their demographic
table describing baseline characteristics.
Single-sex studies Six of the 12 single-sex RCTs
used terms related to gender (men, women, boys) to re-
port the population studied and the other six RCTs use
the terms male and/or female.
Mixed-sex studies Fifteen of 88 RCTs used the term
gender to describe the population and 16 RCTs used the
terms ‘men/women’ to report the population demo-
graphics. Eighty-six RCTs reported the population
demographics according to sex or gender. As noted
above, two RCTs did not provide any description of
population by sex but instead referred to participants as
“patients” (n = 1) [41] or “nurses/care aides” (n = 1) [42].
Statistical analysis of RCTs across sex or gender
Mixed-sex studies Twenty of the 88 RCTs (23%) re-
ported analyses related to sex or gender in the methods
section, but none included a comprehensive sex and
gender analysis across stages of the research process [6].
These statistical methods included randomization strati-
fied by sex or gender (3 RCTs) [43–45], adjusting for sex
Welch et al. Research Integrity and Peer Review  (2017) 2:15 Page 6 of 11
or gender as a covariate (11 RCTs) [37, 46–55] and sub-
group analysis across sex or gender (6 RCTs) [56–61].
The three trials which stratified randomization by sex or
gender did not report subgroup analyses across sex or gen-
der [43–45]. All 11 RCTs that described an intention to
adjust for sex or gender as a variable, adjusted for or in-
cluded sex or gender as a covariate in their analysis model.
For the six RCTs that reported results of subgroup ana-
lyses across sex or gender mentioned above, five RCTs
pre-specified the intention to conduct subgroup analysis
by sex or gender in the methods section. Only four studies
provided sex-disaggregated data across intervention and
comparator arms [51, 58, 60, 62]. For example, a study
looking at effects of Korean red ginseng provides the
mean and standard deviation of the outcome for each
intervention arm and control arm disaggregated for male
and female (pg. 166) [51]. Only one of the six studies that
conducted subgroup analyses discussed the treatment in-
teractions by sex in their discussion of results [60].
Discussion/conclusions of RCTs
Single-sex studies Seven of 12 RCTs reported on sex or
gender in their discussion regarding applicability and
implications. For example, one study examining the ef-
fect of zinc supplementation on copper status in boys re-
ported that “… the results of this study are expected to
be generalizable to girls (pg. 288)” [63].
Mixed-sex studies Eleven of the 88 RCTs reported on
sex or gender implications of their findings. For example,
one study stated that: “…although differences did not at-
tain statistical significance, women were overrepresented
in the SBI (ed: spiritually based intervention) and the ex-
tent to which findings can be fully extended to men is not
clear (pg.504)” [64]. A study on colorectal cancer screen-
ing concluded: “Our results confirm those reported in that
FOBT (ed: fecal occult blood test) uptake tends to increase
with age among men and women (pg.9)” [65].
Discussion
We found no examples of sex and gender analysis in a sam-
ple of 100 Canadian-led or funded RCTs [24, 27, 66].
Where sex and gender were considered, these consider-
ations were often limited and mainly focused on biomedical
analysis of differences across sex. For example, no studies
considered the influence of gender. Only 6% (six studies) of
our sample reported subgroup analyses across sex or gen-
der. This was despite the fact that over 50% of our sample
of RCTs evaluated non-pharmacologic interventions such
as decision aids, cognitive therapy, self-help education tools,
and community-based interventions where gender may play
an important role in how the intervention is delivered (by
whom and in what context) and received. Furthermore, of
the six RCTs with subgroup analysis, only one commented
in any depth on the methodological challenges of conduct-
ing sub-group analysis or on the significance of their find-
ings and implications for clinical practice. We also noted
inconsistent use of terminology in some RCTs, with sex and
gender being used without definition and sometimes inter-
changeably. In RCTs, information on eligibility and recruit-
ment forms is usually collected as “male/female”, and the
use of the term “gender” may be inaccurate. These findings
are consistent with those of recent studies looking at sex-
related reporting in randomized trials published in major
medical journals [23, 67]. Clarity in the application of the
conceptual constructs of sex and gender and of sex and
gender analysis is an important component of scientific
rigor and contributes to the growing understanding of the
ways that sex-based biological factors and gendered social
factors are intertwined and interact with other social fac-
tors, shaping health behavior, opportunities, and outcomes
[5, 24, 68–70].
The credibility and clinical importance of sex-based
subgroup analyses must be carefully scrutinized since
there is a risk of spurious findings due to under-powered
tests and multiple testing. A recent meta-synthesis found
that statistically significant effects of sex on treatment re-
sponse in randomized trials were rarely reported, and
when they were, they were rarely confirmed in subsequent
trials or in meta-analyses, and very rarely led to a recom-
mendation for differential treatment [71]. However, exam-
ples where differential treatment has been recommended
(e.g., weight management for men by Public Health
England [72], statin management [71], and differential
dosage recommendations based on a differential risk-
benefit ratio for Ambien (Zolpidem) [73], justify the need
for sex and gender analysis in trials. The lack of data and
analysis about women and coronary heart disease (due to
exclusion of women from some clinical trials) is postu-
lated as one of the reasons for under-treatment of women
with symptoms of ischaemic heart disease [74]. There is a
need for an improved evidence-base and for robust meth-
odologies to determine differences and similarities of ef-
fects across sex and gender [6].
A variety of initiatives are attempting to address incon-
sistent terminology and the lack of robust sex and gender
analysis in health research. For example, the Canadian In-
stitutes of Health Research has published a casebook [66]
and a tool for peer reviewers of grants and/or papers [27],
a major advancement in promoting appropriate sex and
gender analysis in research [75]. The SAGER (Sex and
Gender Equity in Research) guidelines were developed by
the Gender Policy Committee of the European Associ-
ation of Science Editors (EASE) for reporting sex and gen-
der in all types of science publications [31]. At the same
time, academic journals are putting in place editorial pol-
icies that require sex-specific or gender-specific reporting
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[76]. Members of our team have recently developed
reporting guidelines for health equity relevant RCTs, as an
extension of the CONSORT statement (Consolidated
Reporting of Randomized Trials) [77] and briefing notes
to improve the consideration of sex and gender in system-
atic reviews [3]. All of these tools can be used by authors
of RCTs to improve reporting of sex and gender.
More initiatives are needed to implement these and
other tools and encourage their use to address the lack
of sex and gender analysis in trials. Different strategies
may be needed to tailor these initiatives for specific au-
diences such as trialists, funders, journal editors, pa-
tients/public, and policy-makers [78].
Furthermore, in our study, there were no RCTs that
mentioned gender diverse populations. As knowledge of
sex and gender analysis develops, approaches to study
design and analysis need to keep current with clear and
consistent terminology to support gender-sensitive
decision-making [6].
This study examined reporting of sex, gender, and sex
and gender analysis in a sample of Canadian RCTs, where
sectors of the funding environment are actively promoting
inclusion of sex and gender analysis in all research [26].
Although our study reviewed only a small cross-section of
Canadian RCTs, our findings suggest that despite policies
to encourage sex and gender analysis we are not yet seeing
impacts in terms of sex and gender reporting in RCTs and
uptake of sex and gender analysis. Reporting sex and gen-
der considerations in peer-reviewed publications is a key
indicator of whether policy efforts to mandate and en-
courage sex and gender analysis are effective. Thus, it will
be important to continue to monitor changes in reporting
over time to determine whether policy interventions are
delivering their intended outcomes and develop new ap-
proaches for increasing skill level in the research and
knowledge user communities.
This preliminary study has a number of limitations. This
study is limited to what is reported in the included RCTs.
It is possible that the effects of sex and/or gender on re-
sponse were tested in more studies but not reported. Also,
this sample of RCTs includes relatively small RCTs (with a
median of 100 participants) and many of the studies
would be underpowered to detect differences in response
across sex or gender. In the six RCTs which did conduct a
subgroup analysis across sex or gender, we did not assess
the power for this analysis, nor the quality of these ana-
lyses because we expected there to be too few studies with
these analyses to be generalizable to other situations. An-
other limitation is that our definition of “Canadian” trials
may have missed or under-selected multi-national trials.
We did not collect whether the flow of participants was
reported according to gender (e.g., recruited, enrolled,
completed), and this information would be important for
conducting a sex and gender-based analysis. We also did
not contact authors to obtain any additional details about
sex and gender analysis, methods, or results. As well, the
findings in this study may not be extrapolated to RCTs
conducted primarily in other countries, due to the focus
on Canadian RCTs, although some studies included mul-
tiple non-Canadian sites [23, 79].
Conclusions
This survey of a sample of Canadian RCTs reveals very lit-
tle analysis of differences or similarities in health out-
comes across sex and/or gender, and no clear attempts on
the part of researchers to integrate elements of sex and
gender analysis. Furthermore, there was no mention of in-
clusion or exclusion of gender diverse people. This study
provides a baseline and methodological approach to com-
pare and assess changes in reporting about sex and gender
and in the application of sex and gender analysis in future
Canadian RCTs, and adds to global and Canadian efforts
to make the case for integrating sex and gender analysis in
health research. This study demonstrates a need for con-
tinued efforts to improve appropriate consideration and
reporting of sex and gender and the integration of sex and
gender analysis in randomized trials so that ultimately
health services and policies address the needs of diverse
populations and improve health outcomes for all.
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